299 related articles for article (PubMed ID: 26575690)
1. RNA splicing, cell signaling, and response to therapies.
Abou Faycal C; Gazzeri S; Eymin B
Curr Opin Oncol; 2016 Jan; 28(1):58-64. PubMed ID: 26575690
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
3. Splicing Factor Mutations in Cancer.
Bejar R
Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
[TBL] [Abstract][Full Text] [Related]
4. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
[TBL] [Abstract][Full Text] [Related]
5. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
Boultwood J; Dolatshad H; Varanasi SS; Yip BH; Pellagatti A
Adv Biol Regul; 2014 Jan; 54():153-61. PubMed ID: 24080589
[TBL] [Abstract][Full Text] [Related]
6. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.
Kim E; Ilagan JO; Liang Y; Daubner GM; Lee SC; Ramakrishnan A; Li Y; Chung YR; Micol JB; Murphy ME; Cho H; Kim MK; Zebari AS; Aumann S; Park CY; Buonamici S; Smith PG; Deeg HJ; Lobry C; Aifantis I; Modis Y; Allain FH; Halene S; Bradley RK; Abdel-Wahab O
Cancer Cell; 2015 May; 27(5):617-30. PubMed ID: 25965569
[TBL] [Abstract][Full Text] [Related]
7. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
Taylor J; Lee SC
Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
[TBL] [Abstract][Full Text] [Related]
8. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
9. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities.
Zhang J; Lieu YK; Ali AM; Penson A; Reggio KS; Rabadan R; Raza A; Mukherjee S; Manley JL
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):E4726-34. PubMed ID: 26261309
[TBL] [Abstract][Full Text] [Related]
10. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.
Visconte V; Makishima H; Maciejewski JP; Tiu RV
Leukemia; 2012 Dec; 26(12):2447-54. PubMed ID: 22678168
[TBL] [Abstract][Full Text] [Related]
11. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
[TBL] [Abstract][Full Text] [Related]
12. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
13. Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.
Brunner AM; Steensma DP
Hematol Oncol Clin North Am; 2020 Apr; 34(2):379-391. PubMed ID: 32089217
[TBL] [Abstract][Full Text] [Related]
14. Development of a high-resolution melting curve analysis screening test for SRSF2 splicing factor gene mutations in myelodysplastic syndromes.
Garza E; Fabiani E; Noguera N; Panetta P; Piredda ML; Borgia L; Maurillo L; Catalano G; Voso MT; Lo-Coco F
J Mol Diagn; 2015 Jan; 17(1):85-9. PubMed ID: 25445211
[TBL] [Abstract][Full Text] [Related]
15. [Deregulated splicing machinery in myelodysplastic syndromes].
Ogawa S
Rinsho Ketsueki; 2012 May; 53(5):493-6. PubMed ID: 22728550
[No Abstract] [Full Text] [Related]
16. SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.
Komeno Y; Huang YJ; Qiu J; Lin L; Xu Y; Zhou Y; Chen L; Monterroza DD; Li H; DeKelver RC; Yan M; Fu XD; Zhang DE
Mol Cell Biol; 2015 Sep; 35(17):3071-82. PubMed ID: 26124281
[TBL] [Abstract][Full Text] [Related]
17. [Point mutations of genes encoding proteins involvedin RNA splicing in patients with myelodysplastic syndromes].
Barańska M; Czerwińska-Rybak J; Gil L; Komarnicki M
Pol Merkur Lekarski; 2015 Jan; 38(223):5-10. PubMed ID: 25763580
[TBL] [Abstract][Full Text] [Related]
18. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
[TBL] [Abstract][Full Text] [Related]
19. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
Scott LM; Rebel VI
J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
[TBL] [Abstract][Full Text] [Related]
20. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
